FDA grants supplemental ANDA approval for Glenmark’s Monroe unit
Category: #health  By Saipriya Iyer  Date: 2018-06-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

FDA grants supplemental ANDA approval for Glenmark’s Monroe unit

Glenmark Pharmaceuticals, a pharma firm based in Mumbai, has received a green signal from U.S. FDA for its drug manufactured at Monroe at North Carolina facility. Incidentally, the approval has been granted for the production of atovaquone and proguanil hydrochloride tablets. These drugs are a generic version of Malarone by GlaxoSmithKline, used for treating malaria, claim sources.

If reports are to be believed, this is the first time that Glenmark has received a supplemental Abbreviated New Drug Application (ANDA) approval from the FDA. Robert Matsuk, President, North America & Global API, Glenmark Pharmaceuticals Ltd, was quoted stating that the approval demonstrates an important achievement for the company’s U.S. business. He further claimed that that the Monroe drug manufacturing site will help Glenmark expand its product line, thereby providing a base for the firm’s future drug approvals.

Sources cite that the Monroe-based unit is the firm’s first drug manufacturing site across the U.S. and had been set up to produce myriad fixed dose drug formulations. For the record, the Indian based pharma company has made investments worth over USD 100 million in the drug manufacturing factory and is planning to expand over the next few years.

FiercePharma has recorded Robert Mastuk’s statement that defends the firm’s investment in Monroe facility and claims that the unit will generate high-quality jobs for the Monroe community, where the company is committed to long-term business expansion.

The North Carolina establishment of Glenmark is expected to manufacture approximately 300-400 million tablets & capsules. The company is also projected to produce 20-25 million vials, pre-filled medical syringes, and 25-30 million ampoules for inhaled formulations.

Authentic reports have claimed that the Mumbai-based drug company has 16 medicine production units across Europe, U.S., and India. The firm has 8 new drug candidates across various therapeutic sectors. Reportedly, during the fourth quarter of FY18, the Indian unit of Glenmark accounted for 27% of the firm’s overall revenue, while the U.S. division contributed approximately 31% towards the total revenue.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Foodics enters Egypt market by setting an on-ground presence in Cairo
Foodics enters Egypt market by setting an on-ground presence in Cairo
By Saipriya Iyer

Saudi Arabia-based restaurant management platform Foodics, has announced that it has entered the Egyptian market by creating an on-the-ground presence in Cairo.  The expansion comes after the company raised USD 4 ...

Food Emulsifiers Market to Witness an Appreciable Growth By 2026
Food Emulsifiers Market to Witness an Appreciable Growth By 2026
By Saipriya Iyer

This advanced report on the Food Emulsifiers Market includes of an in-depth overview of this business sphere. Alongside, details of the present market size and status have been given. The report aims to provide substantial updates on the market, p...

Bharat Biotech reveals positive data from animal trial of Covaxin
Bharat Biotech reveals positive data from animal trial of Covaxin
By Saipriya Iyer

Bharat Biotech, an Indian biotechnology company, has reportedly revealed positive results from the animal trial of Covaxin, India’s COVID-19 vaccine candidate.

In the animal t...